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•

Multiple Myeloma (MM) is the neoplastic proliferation of
plasma cells leading to an increase in monoclonal
immunoglobulins. The infiltration of plasma cells into various
organs leads to the common clinical presentation of
hypercalcemia, renal insufficiency, anemia, and bone
disease.

•

Multiple Myeloma is most commonly seen in older adults,
men more so than women, with an average age of sixty-five
to seventy-four years. We present an unique case
concerning a 44-year-old male presenting with malaise and
shortness of breath.

Vitals:
T: 37.2°C
P: 130 bpm
RR: 22rpm
BP:106/68 mmHg
O2 Sat: 98% on RA
BMI: 39.4

Case Description
• A 44-year-old male with no known past medical
history presented with worsening shortness of
breath, increasing malaise, and atypical chest pain.
Several abnormalities were noted on initial labs,
which included acute kidney injury with an
elevated creatinine of >28 mg/dL, uremia with a
BUN 231 mg/dL, anion gap metabolic acidosis with
a carbon dioxide of 8 mmol/L, hyperkalemia, and
severe normocytic anemia (Hgb 6.9 g/L) with no
reported source of bleeding. Imaging revealed
extensive lytic lesions throughout the calvarium,
spine, pelvis, ribs, and sternum.

Discussion

Physical Exam

Background

General Appearance: alert, awake, oriented,
pleasant, mental status normal
Neck: no JVD, no lymphadenopathy
Cardiovascular: irregularly irregular, tachycardic
Respiratory: clear to auscultation, no distress, on
room air
Abdomen: soft, non-tender, no distention
Extremities: moves all, no edema, no calf
tenderness, normal temperature
Skin: dry, intact, no rash
Neuro: alert and oriented x 4, no neuro deficits

Labs and Imaging

Serum Potassium

Patient

Normal Range

5.7 mmol/L

3.4-5.0 mmol/L

CO2
8 mmol/L
BUN/Cr
231/ >28 mg/dL
Hgb
6.9 g/L
SPEP/UPEP
M spike: Not observed
Immunofixation
IgG Kappa
Kappa/Lambda
45
Ratio
FISH
Gain of 9, del 1p, del of 17p
Bone Marrow Bx 20-30% clonal plasma cells

22-30 mmol/L
7-17/0.5-1.0 mg/dL
12.0-16.0 g/dL
--1.03-31.76
---

CT Head w/o Contrast: Extensive lytic destructive lesions throughout the calvarium.

• The patient was admitted to the intensive care unit
for emergent dialysis and underwent further workup
for concern of MM. Serum and urine protein
electrophoresis (SPEP, UPEP) were negative for a
monoclonal spike. However, immunofixation was
remarkable for IgG kappa monoclonal protein.
Beta 2 microglobulin was found to be elevated at
38.5mg/L and LDH and albumin were normal.
Bone marrow biopsy revealed plasma cell myeloma
with 20-30% clonal plasma cells. Kappa/Lambda
light chain ratio was found to be 45.9.
Fluorescence in situ hybridization (FISH) studies
revealed gain of chromosome 9, deletion of 1p
and loss of P53 in chromosome 17. Clinically, the
patient improved after dialysis and, after placement
of a tunnel catheter for dialysis, was stable to be
discharged from the hospital and followed up with
hematology-oncology for further outpatient care.

CT Chest, Abdomen, and Pelvis w/o Contrast: Widespread osseous metastatic
disease seen throughout the visualized spine, pelvis, ribs, and sternum.
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•Multiple myeloma is increasingly seen as a heterogeneous
disease with its overall survival determined by multiple factors.
Patient characteristics, cytogenetics, and clinical features are
used to risk stratify newly diagnosed MM.
–An analysis of 10,549 MM patients, with 1689 patients
younger than 50 years old showed more favorable
features such as low risk staging and less frequent adverse
prognostic factors in this age group.
–Despite our patient’s young age at diagnosis, which is seen
in about 3% of cases, his clinical presentation and
cytogenetics categorize him as high risk.
–Our patient’s FISH analysis revealed a deletion of 1p and
loss of P53 in chromosome 17, contributing to the high risk
nature of the patient’s multiple myeloma. The frequency of
these chromosomal abnormalities are 30% and 10%,
respectively.
•While survival for standard risk MM has greatly improved due to
novel treatments, high risk MM continues to have poor
prognosis.
•Correctly staging the high risk newly diagnosed MM patients
becomes imperative as treatment strategies are chosen for
these individuals and must involve the various factors that play
an influential role in the overall survival.
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